Radiopharm Theranostics Ltd ADRRAD
Price$1.48

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.6M0.0% YoYTTM through 30 Jun 2025
Net Income -$38.3MTTM through 30 Jun 2025
Free Cash Flow -$36.7MTTM through 30 Jun 2025

Margins

Current
Gross Margin7.4%
Operating Margin-1,050.6%
Net Margin-1,055.3%

Returns

-94.0%ROE
-51.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.22x
Net Debt-$34.5Mnet cash position
Cash & Equivalents$29.1M

Quality Metrics

Piotroski F-Score4 / 9
FCF Margin-1,009.8%

Multi-Year Trend

Revenue
'25
FY2025: $3.6M
Diluted EPS
'23'24'25
FY2025: $-0.02

Dividend

No dividend

Capital Allocation

Capex Intensity1.2%

Segment Performance

No segment data available.

Financials converted at 1.5202 from AUD.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.